These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 15670247

  • 1. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI, Aboulhab J.
    HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 Jan; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 3. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 4. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R, Asmuth DM, Grady JJ, McKinsey DS, Green S, Andron L, Pollard RB.
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [Abstract] [Full Text] [Related]

  • 5. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
    Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Scudeller L, Tinelli C, D'Aquila R, Lisziewicz J, Lori F.
    Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
    Stebbing J, Nelson M, Orkin C, Mandalia S, Bower M, Pozniak A, Gazzard B.
    J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
    [Abstract] [Full Text] [Related]

  • 7. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
    Clotet B, Ruiz L, Cabrera C, Ibáñez A, Cañadas MP, Sirera G, Romeu J, Vila J.
    Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
    [Abstract] [Full Text] [Related]

  • 8. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 9. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R, Portilla J, Gimeno A, Boix V, Llopis C, Sanchez-Paya J, Merino E, de la Sen ML, Muñoz C, Reus S, Plazas J.
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C, Soriano V, Pérez-Olmeda M, Rodríguez-Rosado R, González-Lahoz J.
    J Hum Virol; 2000 Feb; 3(6):335-40. PubMed ID: 11100914
    [Abstract] [Full Text] [Related]

  • 11. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA, Cheingsong R, Garcìa-Lerma JG, Eholié S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W, Nkengasong JN.
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [Abstract] [Full Text] [Related]

  • 12. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
    Clevenbergh P, Boulmé R, Kirstetter M, Dellamonica P.
    HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
    [Abstract] [Full Text] [Related]

  • 13. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [Abstract] [Full Text] [Related]

  • 14. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
    Seyler C, Adjé-Touré C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D, Nolan M, Toure S, Anglaret X.
    AIDS; 2007 May 31; 21(9):1157-64. PubMed ID: 17502726
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of a didanosin-containing regimen including genotypic resistance testing: an open-label, multicenter study.
    Treichel S, Hartmann M, Rump A, Brust J, Schuster D, Mosthaf F, Procaccianti M, Klinker H, Petzoldt D.
    Eur J Med Res; 2003 Sep 29; 8(9):405-13. PubMed ID: 14555296
    [Abstract] [Full Text] [Related]

  • 16. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
    Hellinger JA, Iwane MK, Smith JJ, Fleishman AN, Torres RA, Schrader S, Perez G, Cohen CJ, Skowron G, Giordano MF, Accetta G, Cooper EC, Frost KR.
    J Infect Dis; 2000 Feb 29; 181(2):540-7. PubMed ID: 10669337
    [Abstract] [Full Text] [Related]

  • 17. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 18. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F, Reliquet V, Francois C, Garre M, Hascoet C, Allavena C, Arvieux C, Breux JP, Perre P, Rozenbaum W, Auger S.
    Antivir Ther; 1998 Aug 01; 3 Suppl 4():57-60. PubMed ID: 10723512
    [Abstract] [Full Text] [Related]

  • 19. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct 01; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

  • 20. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A.
    Infection; 2007 Dec 01; 35(6):451-6. PubMed ID: 18034204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.